Tvardi Therapeutics (TVRD) Stock Forecast, Price Target & Predictions
TVRD Stock Forecast
Tvardi Therapeutics (TVRD) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $10.67, with a high of $13.00 and a low of $9.00. This represents a 804.24% increase from the last price of $1.18.
TVRD Stock Rating
Tvardi Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 2 Buy (50.00%), 1 Hold (25.00%), 1 Sell (25.00%), and 0 Strong Sell (0.00%).
Buy
TVRD Price Target Upside V Benchmarks
| Type | Name | Upside |
|---|---|---|
| Stock | Tvardi Therapeutics | 804.24% |
| Sector | Healthcare Stocks | 15.45% |
| Industry | Biotech Stocks | 41.48% |
Price Target Trends
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $8.75 |
| Last Closing Price | $1.18 | $1.18 | $1.18 |
| Upside/Downside | - | - | 641.53% |
Ratings Trends
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell | Total |
|---|---|---|---|---|---|---|
| Nov, 26 | 2 | 6 | 1 | - | 1 | 10 |
| Oct, 26 | 2 | 5 | 1 | - | 1 | 9 |
| Sep, 26 | 2 | 5 | 1 | - | 1 | 9 |
| Aug, 26 | 2 | 5 | 1 | - | 1 | 9 |
| Jul, 26 | - | 5 | 3 | - | 1 | 9 |
Analyst Price Target Forecasts
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 08, 2026 | Piper Sandler | $13.00 | $5.00 | 160.00% | 1001.69% | |
| Jul 08, 2026 | Ryan Deschner | UBS | $10.00 | $3.10 | 222.58% | 747.46% |
| Jun 08, 2026 | H.C. Wainwright | $9.00 | $2.89 | 211.42% | 662.71% | |
| Apr 20, 2026 | Barclays | $3.00 | $3.39 | -11.50% | 154.24% | |
| Oct 13, 2025 | Barclays | $5.00 | $6.69 | -25.26% | 323.73% | |
| Oct 13, 2025 | Yasmeen Rahimi | Piper Sandler | $4.00 | $6.54 | -38.84% | 238.98% |
| Oct 13, 2025 | Etzer Darout | Barclays | $61.00 | $41.60 | 46.63% | 5069.49% |
| Jun 12, 2025 | Yasmeen Rahimi | Piper Sandler | $78.00 | $26.11 | 198.74% | 6510.17% |
Analyst Rating Forecasts
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 08, 2026 | Piper Sandler | Neutral | Overweight | upgrade |
| Jul 08, 2026 | UBS | Outperform | upgrade | |
| Jun 08, 2026 | H.C. Wainwright | Buy | initialise | |
| Apr 20, 2026 | Barclays | Negative | Underweight | downgrade |
| Oct 14, 2025 | Raymond James | Outperform | Market Perform | downgrade |
| Oct 13, 2025 | Barclays | Overweight | Negative | downgrade |
| Oct 13, 2025 | Cantor Fitzgerald | Overweight | Neutral | downgrade |
| Oct 13, 2025 | Piper Sandler | Overweight | Neutral | downgrade |
| Oct 13, 2025 | Barclays | Overweight | initialise | |
| Jul 14, 2025 | Raymond James | Outperform | initialise |
Financial Forecast
EPS Forecast
Annual
| Dec 25 | Dec 26 | Dec 27 | |
|---|---|---|---|
| Reported | - | - | - |
| Avg Forecast | $-3.16 | $-4.60 | - |
| High Forecast | $-3.16 | $-4.60 | - |
| Low Forecast | $-3.16 | $-4.60 | - |
| Surprise % | - | - | - |
Revenue Forecast
Annual
| Dec 25 | Dec 26 | Dec 27 | |
|---|---|---|---|
| Reported | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Net Income Forecast
Annual
| Dec 25 | Dec 26 | Dec 27 | |
|---|---|---|---|
| Reported | - | - | - |
| Avg Forecast | $-29.56M | $-43.04M | - |
| High Forecast | $-29.56M | $-43.04M | - |
| Low Forecast | $-29.56M | $-43.04M | - |
| Surprise % | - | - | - |